课题基金 / 基金详情

Inhibition of superantigen-induced apoptosis by LPS

Inhibition of superantigen-induced apoptosis by LPS
LPS 抑制超抗原诱导的细胞凋亡
批准号:
12671759
负责人:
RIKIISHI Hidemi
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

RIKIISHI Hidemi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Studies of the events triggered by bacterial superantigens provide rich insight into the constant battle between microbes and the immune system. In this study, we demonstrated a mechanism of apoptosis induced by staphylococcal enterotoxin B (SEB) in monocytes and some evidence for the anti-apoptotic function in CD80^+ monocytes. Pretreatment with pyrrolidine dithiocarbamate (PDTC), a potent inhibitor of NF-κB, resulted in significant reduction of the percentages of SEB-and IFN-γ (produced by SEB)-induced CD80^+ monocytes. Monocytes expressed constitutive NF-κB binding activity, and SEB and IFN-γ further activated NF-κB, which was inhibited by pretreatment with PDTC. Apoptosis of monocytes was enhanced by the addition of SEB. Increases in soluble CD95 ligand (sCD95L) levels were observed following stimulation with SEB, but not IFN-γ. Our results demonstrated that SEB treatment induced the activation of caspase-3 and -8, and pretreatment with z-VAD-fmk, a broad-spectrum inhibitor of caspases, prevented the induction of apoptosis at 24 h. CD80^- monocytes were sensitive to apoptosis, and survival of CD80^- monocytes from apoptosis by treating with z-VAD-fmk resulted in reduction of the percentages of CD80^+ monocytes. PDTC abolished anti-apoptotic function in those treated with IFN-γ. Thus, our results indicated that SEB stimulation includes both anti-apoptotic action through NF-κB activation by IFN-γ and pro-apoptotic action through sCD95L released by SEB, and that CD80 driven by NF-κB allows monocytes to participate in distinct survival programs and massive T-cell activation.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
S. Sugawara: "Monocytic cell activation by nonendotoxic glycoprotein from P. intermedia ATCC 25611 is mediated by TLR2"Infection and Immunity. 69 (8). 4951-4957 (2001)
S. Sukawara:“来自 P. intermedia ATCC 25611 的非内毒性糖蛋白的单核细胞激活是由 TLR2 介导的”感染和免疫。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
S.Sugawara: "Monocytic cell activation by nonendotoxic glycoprotein from P.intermedia ATCC 25611 is mediated by TLR2"Infection and Immunity. 69(8). 4951-4957 (2001)
S.Sukawara:“来自 P.intermedia ATCC 25611 的非内毒性糖蛋白的单核细胞激活是由 TLR2 介导的”感染和免疫。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
M.Takahashi: "Effects of superantigen and lipopolysaccharide on induction of CD80 through apoptosis of human monocytes"Infection and Immunity. (発表予定). (2001)
M. Takahashi:“超抗原和脂多糖对通过人类单核细胞凋亡诱导 CD80 的影响”《感染与免疫》(即将出版)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
S.Sugawara: "Monocytic cell activation by nonendotoxic glycoprotein from P. intermedia ATCC 25611 is mediated by TLR2"Infection and Immunity. 69(8). 4951-4957 (2001)
S.Sukawara:“来自 P. intermedia ATCC 25611 的非内毒性糖蛋白的单核细胞激活是由 TLR2 介导的”感染和免疫。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    Mechanisms of Taxotere-induced apoptosis in or a squamous cell carcinoma.
    • 批准号:
      16390577
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $6.66万
    • 财政年份:
      2004
    • 负责人:
      RIKIISHI Hidemi
    • 依托单位:
    Selective apoptosis during treatment with superantigen and lipopolysaccharide
    • 批准号:
      14571726
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.79万
    • 财政年份:
      2002
    • 负责人:
      RIKIISHI Hidemi
    • 依托单位:
    The etiological significance of superantigen in periodontal disease and its possible role
    • 批准号:
      10671695
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.98万
    • 财政年份:
      1998
    • 负责人:
      RIKIISHI Hidemi
    • 依托单位:
    Induction of cytokines by oral bacterial stimulation and its arthropathic properties
    • 批准号:
      02670824
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.34万
    • 财政年份:
      1990
    • 负责人:
      RIKIISHI Hidemi
    • 依托单位:
    国内基金
    海外基金
    基于肠道菌群探讨健脾化痰方通过调节LPS/NF-κB信号通路改善多囊卵巢综合征的机制研究
    • 批准号:
      2026JJ80146
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      余曦明
    • 依托单位:
    基于肠道微生态的他莫昔芬-LPS-OTUD6A-HDAC3轴诱导乳腺癌内分泌治疗耐药的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      祝琦
    • 依托单位:
    肺炎克雷伯菌WaaLCPS连接酶相关的CPS-LPS合成通路及致病机制的研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      何平
    • 依托单位: